Cargando…

Exploiting inflammation for therapeutic gain in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steele, C W, Jamieson, N B, Evans, T R J, McKay, C J, Sansom, O J, Morton, J P, Carter, C R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619061/ https://www.ncbi.nlm.nih.gov/pubmed/23385734 http://dx.doi.org/10.1038/bjc.2013.24

Ejemplares similares

The role of PARP in DNA repair and its therapeutic exploitation
por: Javle, M, et al.
Publicado: (2011)

Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2009)

The Generation and Exploitation of Protein Mutability Landscapes for Enzyme Engineering
por: van der Meer, Jan‐Ytzen, et al.
Publicado: (2016)

Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
por: Killeen, S D, et al.
Publicado: (2006)

Stem vs non-stem cell origin of colorectal cancer
por: Huels, D J, et al.
Publicado: (2015)

Hacking the Cell: Network Intrusion and Exploitation by Adenovirus E1A
por: King, Cason R., et al.
Publicado: (2018)

Exploiting pathogens' tricks of the trade for engineering of plant disease resistance: challenges and opportunities
por: Grant, Murray R, et al.
Publicado: (2013)

Pancreatic cancer stem cells: Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma
por: Di Carlo, Claudia, et al.
Publicado: (2018)

Targeting LKB1 in cancer – exposing and exploiting vulnerabilities
por: Momcilovic, M, et al.
Publicado: (2015)

Exploiting Interdata Relationships in Next-generation Proteomics Analysis
por: Vitrinel, Burcu, et al.
Publicado: (2019)

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy
por: Jo, Ukhyun, et al.
Publicado: (2015)

CXCR2 inhibition suppresses acute and chronic pancreatic inflammation
por: Steele, Colin W, et al.
Publicado: (2015)

Molecular therapeutic strategies targeting pancreatic cancer induced cachexia
por: Yakovenko, Anastasiya, et al.
Publicado: (2018)

Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities
por: Manrai, Manish, et al.
Publicado: (2021)

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets
por: Chen, Shao-Long, et al.
Publicado: (2021)

Current role of palliative interventions in advanced pancreatic cancer
por: Ciambella, Chelsey C, et al.
Publicado: (2018)

Cancer and systemic inflammation: treat the tumour and treat the host
por: Roxburgh, C S D, et al.
Publicado: (2014)

Therapeutic plasma exchange for hyperlipidemic pancreatitis: Current evidence and unmet needs
por: Zheng, Can-Bin, et al.
Publicado: (2021)

Role of human nucleoside transporters in pancreatic cancer and chemoresistance
por: Carter, Carly Jade, et al.
Publicado: (2021)

Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
por: Elaskalani, Omar, et al.
Publicado: (2017)

Cancer heterogeneity: implications for targeted therapeutics
por: Fisher, R, et al.
Publicado: (2013)

Exploiting epidemiological data to understand the epidemiology and factors that influence COVID-19 pandemic in Libya
por: Mahmoud, Abdusalam S, et al.
Publicado: (2021)

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
por: Gilbert, D C, et al.
Publicado: (2012)

Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target
por: Buczacki, S, et al.
Publicado: (2011)

Recent advances in the diagnostic evaluation of pancreatic cystic lesions
por: Ardeshna, Devarshi R, et al.
Publicado: (2022)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

T cells in pancreatic cancer stroma
por: Goulart, Michelle R, et al.
Publicado: (2021)

Pancreatic acinar cell carcinoma: A comprehensive review
por: Calimano-Ramirez, Luis Fernando, et al.
Publicado: (2022)

Hereditary pancreatitis: An updated review in pediatrics
por: Panchoo, Arvind Vasant, et al.
Publicado: (2022)

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest
por: Morton, Jennifer P., et al.
Publicado: (2010)

Targeting telomerase for cancer therapeutics
por: Shay, J W, et al.
Publicado: (2008)

Overview and comparison of guidelines for management of pancreatic cystic neoplasms
por: Hasan, Aws, et al.
Publicado: (2019)

Molecular classification of solid tumours: towards pathway-driven therapeutics
por: Swanton, C, et al.
Publicado: (2009)

Post-acute pancreatitis diabetes: A complication waiting for more recognition and understanding
por: García-Compeán, Diego, et al.
Publicado: (2023)

Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach
por: Rajesh, Srujan, et al.
Publicado: (2021)

Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer
por: Petrov, Maxim S
Publicado: (2021)

Therapeutic plasma exchange in liver failure
por: Chris-Olaiya, Abimbola, et al.
Publicado: (2021)

Oncogenic AKTivation of translation as a therapeutic target
por: Hsieh, A C, et al.
Publicado: (2011)

Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations
por: Poddighe, Dimitri
Publicado: (2021)

Current status of treatments of pancreatic and peripancreatic collections of acute pancreatitis
por: Xiao, Nian-Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r13j384kisp6qfn5pq27dv45f0